Korean Regulatory Overhaul To Cut Drug RnD, Approval Time
This article was originally published in SRA
Executive Summary
The South Korean government has unveiled a series of regulatory reforms that are designed to step up the competitiveness of the pharma industry and supply drugs in time for public health emergencies.
You may also be interested in...
2016 Review: Despite Political Woes, Korea Pro-Pharma Policies Stay Intact
2016 has been full of shock and despair in South Korea’s political scene. But when it comes to the country’s biopharma policy, the year has seen fewer surprising or dramatic events.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.
Window Of Opportunity: Korea Unveils Cutting-Edge Bio Initiative
South Korea is moving forward with plan to set up a Boston-type biotech cluster in Osong as part of a broader initiative unveiled by President Yoon, while the biopharma industry is calling for rapid process, exceptional support.